Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III

Figures

• 

  Figure 1. Rates of target lesion failure at 12 months by the region of recruitment. (A) Target lesion failure by site of recruitment (y-axis). (B) Target lesion failure by the site of recruitment in the Supreme DES cohort (y-axis). Target lesion failure is a composite of cardiac death, target vessel–related myocardial infarction, or clinically driven target lesion revascularization. DES, drug-eluting stents.

• 

  Figure 2. Rates of target lesion failure at 12 months by region of recruitment and stent used. Target lesion failure in Supreme DES vs DP-EES (y-axis) at sites in (A) North America, (B) Europe, and (C) Japan. Target lesion failure is a composite of cardiac death, target vessel–related myocardial infarction, or clinically driven target lesion revascularization. DES, drug-eluting stents; DP-EES, durable polymer everolimus-eluting stents; HR, hazard ratio.

• 

  Central Illustration. Geographic variations on the safety and efficacy of Supreme biodegradable polymer drug-eluting stents. BMI, body mass index; DES, drug-eluting stent; DM, diabetes mellitus; DP-EES, durable polymer everolimus-eluting stents; FFR, fractional flow reserve; IVUS, intravascular ultrasound; MACE, major adverse cardiac events; MI, myocardial infarction; NSTEMI, non–ST-segment elevation MI; TLF, target lesion failure.

• 

  Figure 3. Rates of target lesion failure at 12 months in high- vs low-recruiting sites. (A) Target lesion failure at high- vs low-recruiting sites (y-axis). (B) Target lesion failure at high- vs low-recruiting sites in the Supreme DES cohort (y-axis). High-recruiting sites recruited ≥20 patients. Low-recruiting sites recruited <20 patients. Target lesion failure is a composite of cardiac death, target vessel–related myocardial infarction, or clinically driven target lesion revascularization. DES, drug-eluting stents; HR, hazard ratio.